杜邦关闭四种清洁水技术采集

德克萨斯州威尔明顿，2020年1月9日-Dupont（纽约证券交易所：DD）今天宣布已完成2019年的Desalitech，Inge GmbH，Memcor®和Oxymem Limited的收购;增加其领先的水净化和分离技术组合，包括超滤，反渗透和离子交换树脂。

这四项最新收购支持了杜邦公司的目标，即增加获得满足全球客户当前和未来挑战所需的产品和技术的机会，包括增加对循环水的需求，同时降低生产清洁水的能源需求。

“水资源短缺是一项全球性挑战，需要以紧迫感加以解决。作为创新水技术领域的全球领导者，我们正在不断扩大高质量解决方案的技术组合，以帮助我们的客户净化、保护和再利用这一宝贵资源，”杜邦水解决方案全球副总裁兼总经理HP Nanda说我们期待着与设备制造商、最终用户和其他价值链合作伙伴在各种商业模式下合作，解决他们面临的水资源挑战并提供卓越的价值。”必威备用网址

最近的收购进一步扩大了杜邦的投资组合，增强了该公司加快创新、为客户提供更好服务水平的能力，同时降低了清洁水的生命周期成本。加入杜邦水解决方案组合的四家公司包括：必威备用网址

• inge gmbh，从巴斯夫收购的超滤膜业务。业界领先的多孔PES超滤技术补充了杜邦的高流量PVDF膜技术。该交易包括在格雷芬贝格，德国的员工，总部和生产现场的业务“国际员工，以及巴斯夫SE所拥有的相关知识产权。
• Memcor®，evoqua水科技公司的超滤和膜生物反应器（MBR）技术部门添加超滤产品组合扩大了杜邦的解决方案膜生物反应器，浸没式和加压超滤系统和其他新应用。该交易包括澳大利亚和大约200名员工的制造工厂。
• 德萨利特有限公司，闭路反渗透（CCRO）公司。Desalitech的CCRO技术解决了核心细分市场（如食品和饮料、市政、微电子、电力和其他）对高水回收率日益增长的需求。该技术增加了杜邦的产品组合，有助于进一步降低水的生命周期成本，提供95%以上的恢复率，使最终用户能够在工业和分散环境中的中小型系统中轻松操作。交易包括该公司（品牌和产品组合）、知识产权和40人的劳动力。
• oxymem limited，一种开发和生产膜充气生物膜反应器（MABR）技术的公司，用于治疗和净化市政和工业废水。该交易包括所有知识产权，60多名员工和一个位于爱尔兰Athlone的一个生产网站。

加上inge和Memcor杜邦在住宅、工业、公用事业、废水和其他专业解决方案等多个细分市场成为领先的超滤供应商.通过添加Desalitech的CCRO，杜邦可以为客户提供更多选择和灵活性，以解决水资源短缺和净化挑战。借助OxyMem的新兴技术，该公司可以更好地支持希望减少二次废水处理占地面积和能源需求的客户。

“这四次收购绝对是与我们的战略保持一致，成为水技术的领先供应商，以更好地为我们的全球客户提供不断发展的需求，”杜邦水解决方案的增长与战略总监Nicole Richards说。必威备用网址“我们期待着与客户和合作伙伴合作，增加获得最佳新分离和净化技术，以解决全球水危机。”

关于杜邦安全与建设

杜邦安全与建筑公司是全球领先者，致力于为水、住所和安全领域的生活基本需求提供创新；通过独特的功能、全球规模和包括杜邦在内的标志性品牌，使其客户赢得竞争™ Corian®、Kevlar®、Nomex®、Tyvek®、GreatStuff™, 泡沫塑料^™和filmtec™。更多关于杜邦水解决方案可以找到必威备用网址//www.ljlcyg.com/water.

关于杜邦

杜邦（纽约证券交易所：DD）是一种全球创新领导者，具有基于技术的材料，配料和解决方案，可帮助改变行业和日常生活。我们的员工采用多样化的科学和专业知识，以帮助客户推进他们的最佳创意，并在包括电子，运输，建筑，水，健康和健康，食品和工人安全的主要市场中提供必要的创新。更多信息可以找到www.ljlcyg.com.

关于前瞻性声明的警示声明
该沟通在联邦证券法中的含义内包含“前瞻性陈述”，包括1933年的“证券法”第27A条，如修订，以及1934年证券交易所第21E条，如修订。在这方面，前瞻性陈述往往地满足预期的未来业务和财务绩效和财务状况，通常包含“期待”等词语“预期”，“打算”，“计划，”“求，”“求，”“请参阅，”“意志”，“\”，“目标，”和类似的表达和这些词的变化或否定。

2019年4月1日，该公司通过按比例分配道氏公司当时流通在外的所有股票的实物股利，将其材料科学业务分离为一家独立的上市公司（“道氏分销”）。该公司于2019年6月1日通过按比例分配Corteva，Inc.当时流通在外的所有股票的实物股息，将其农业业务分离为一家独立的上市公司（“Corteva分配”）。

2019年12月15日，杜邦和IIF宣布，他们已达成最终协议，将杜邦的营养与生物科学业务与IFF合并，交易将导致IFF向杜邦股东发行股份，等待惯例交割条件、其他批准，包括监管和IFF股东的批准。

前瞻性陈述涉及不同程度，不确定和受风险，不确定性和假设的事项，其中许多超出了杜邦的控制，这可能导致实际结果与任何前瞻性陈述中表达的结果不同。前瞻性陈述不保证未来结果。Some of the important factors that could cause DuPont's actual results to differ materially from those projected in any such forward-looking statements include, but are not limited to: (i) the parties’ ability to meet expectations regarding the timing, completion and accounting and tax treatments of the proposed transaction with IFF; changes in relevant tax and other laws, (ii) failure to obtain necessary regulatory approvals, approval, if required, of IFF’s shareholders, anticipated tax treatment or any required financing or to satisfy any of the other conditions to the proposed transaction, (iii) the possibility that unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies that could impact the value, timing or pursuit of the proposed transaction, (iv) risks and costs and pursuit and/or implementation of the separation of the N&B Business, including timing anticipated to complete the separation, any changes to the configuration of businesses included in the separation if implemented, (v) risks and costs related to the Dow Distribution and the Corteva Distribution (together, the “Distributions”) including with respect to achieving all expected benefits from the Distributions; restrictions under intellectual property cross license agreements; non-compete restrictions; incurrence of significant costs in connection with the Distributions, including costs to service debt incurred by the Company to establish the relative credit profiles of Corteva, Dow and DuPont and increased costs related to supply, service and other arrangements that, prior to the Dow Distribution, were between entities under the common control of DuPont; indemnification of certain legacy liabilities of E. I. du Pont de Nemours and Company ("Historical EID") in connection with the Corteva Distribution; and potential liability arising from fraudulent conveyance and similar laws in connection with the Distributions; (vii) failure to effectively manage acquisitions, divestitures, alliances, joint ventures and other portfolio changes, including meeting conditions under the Letter Agreement entered in connection with the Corteva Distribution, related to the transfer of certain levels of assets and businesses; (viii) uncertainty as to the long-term value of DuPont common stock; (ix) potential inability or reduced access to the capital markets or increased cost of borrowings, including as a result of a credit rating downgrade and (x) other risks to DuPont's business, operations and results of operations including from: failure to develop and market new products and optimally manage product life cycles; ability, cost and impact on business operations, including the supply chain, of responding to changes in market acceptance, rules, regulations and policies and failure to respond to such changes; outcome of significant litigation, environmental matters and other commitments and contingencies; failure to appropriately manage process safety and product stewardship issues; global economic and capital market conditions, including the continued availability of capital and financing, as well as inflation, interest and currency exchange rates; changes in political conditions, including tariffs, trade disputes and retaliatory actions; impairment of goodwill or intangible assets; the availability of and fluctuations in the cost of energy and raw materials; business or supply disruption, including in connection with the Distributions; security threats, such as acts of sabotage, terrorism or war, natural disasters and weather events and patterns which could result in a significant operational event for DuPont, adversely impact demand or production; ability to discover, develop and protect new technologies and to protect and enforce DuPont's intellectual property rights; unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities, as well as management's response to any of the aforementioned factors. These risks are and will be more fully discussed in DuPont's current, quarterly and annual reports and other filings made with the U.S. Securities and Exchange Commission, in each case, as may be amended from time to time in future filings with the SEC. While the list of factors presented here is considered representative, no such list should be considered a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on DuPont’s consolidated financial condition, results of operations, credit rating or liquidity. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. DuPont assumes no obligation to publicly provide revisions or updates to any forward-looking statements whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. A detailed discussion of some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-looking statements is included in the section titled “Risk Factors” (Part II, Item 1A) of DuPont’s Quarterly Report on Form 10-Q for the period ended September 30, 2019 and its subsequent reports on Form 10-Q, 10-K and Form 8-K.

# # #

1/9/2020

杜邦™, 杜邦椭圆形标志，以及用™, ℠ 除非另有说明，否则or®归杜邦公司的附属公司所有。

有关更多信息，请联系：

杜邦媒体

丹特纳

+1 302-996-8372

daniel.a.turner@dupont.com.